Aqilion logo
  • About Aqilion
  • Strategy & Business
  • Corporate
  • News
  • Contact
  • About Aqilion
    • About Aqilion
    • CEO Letter
    • Company History
    • Vision & Mission & Values
    • Organization
      • Board
      • Operational Team
    • Sustainability
  • Strategy & Business
    • Business Model
    • Objectives
    • Strategy
    • Project portfolio
      • Oncorena
      • Alhena
      • Alnitak
      • Polaris
      • Laccure
    • Aqilion as a Partner
  • Corporate
    • Governance
    • Organization
      • Board
      • Operational Team
    • Financial Reports
    • News
    • Subscribe
    • Event Calendar
  • News
    • Press Releases
    • Other Articles
    • Subscribe
    • Event Calendar
    • Media Contact
  • Contact

Financial Reports

2018
  • 2020
  • All years
Type of information
  • Annual Reports
  Report
2018 AQILION AB: Annual Report 2018 (in Swedish)
  • Corporate
    • Governance
    • Organization
      • Board
      • Operational Team
    • Financial Reports
    • News
    • Subscribe
    • Event Calendar

Share this page

About Aqilion

Aqilion is a biotech company that focuses on developing new innovative treatments for diseases caused by chronic inflammation and dysfunctional immune reactions such as autoimmune diseases. The company is mainly active in the early phases of drug discovery, from idea to early clinical development.

Aqilion combines its experience from major pharmaceutical companies with the drive and entrepreneurship of small growth companies. With solid experience of business development in innovative biotech and pharmaceutical companies, Aqilion’s experienced team and board have successfully shepherded drugs all the way from discovery to market.

AQILION AB (publ) is a Swedish public limited company headquartered in Helsingborg, Sweden.

Visiting address

AQILION AB

Henckels Torg 3

Helsingborg

Sweden

Postal address

AQILION AB

c/o HETCH AB

Redaregatan 48

SE-252 36 Helsingborg

Sweden

  • Cookie Policy
  • Privacy Policy
© Copyright 2021 AQILION AB (publ)
No
Yes

Aqilion uses cookies in order to optimize your experience and use of our website as well as to be able to analyze the users’ usage of the website. Choose yourself if you would like to accept the cookies. Before you make your choice we encourage you to read our cookie policy. Do you accept our cookie policy?